Clinical pharmacology of non-steroidal anti-inflammatory drugs: A review

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 11, Issue 1, 2012, Pages 52-64

  Bacchi, S ^a   Palumbo, P ^a   Sponta, A ^a   Coppolino, M F ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Adverse effects; Cancer; Cyclo oxygenases; Neuro inflammation; NSAIDs; Prostanoids; Safe NSAIDs

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HYDROGEN SULFIDE; IBUPROFEN; INDOMETACIN; LICOFELONE; LIPOXYGENASE; LUMIRACOXIB; MELOXICAM; MF 63; NAPROXCINOD; NAPROXEN; NIMESULIDE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SULINDAC; THROMBOXANE; TRANSIENT RECEPTOR POTENTIAL ANKYRIN 1 ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOMATOUS POLYP; ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; CANCER RISK; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COLON CANCER; COLON CARCINOMA; COLON POLYP; COLORECTAL ADENOMA; COLORECTAL CANCER; DEGENERATIVE DISEASE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ENZYME INHIBITION; ESOPHAGUS CANCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPERPYREXIA; HYPERTENSION; INCIDENCE; INFLAMMATION; INTESTINE POLYP; KNEE OSTEOARTHRITIS; LIVER TOXICITY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MUSCULOSKELETAL PAIN; NEPHROTOXICITY; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; OSTEOARTHRITIS; OVARY CANCER; PAIN; PARKINSON DISEASE; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER;

EID: 84867491632     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/187152312803476255     Document Type: Review

References (175)

1. Kraemer, S.A.; Meade, E.A.; De Witt, D.L. Prostaglandin endoper-oxide synthase gene structure: Identification of the transcriptional start site and 5'-flanking regulatory sequences. Arch. Biochem. Byophys., 1992, 293, 391-400.
2. Simmons, D.L.; Botting, R.M.; Hla, T. Ciclooxigenase Isozymes:The biology of Prostaglandin Synthesis and Inhibition. Pharmacol. Rev., 2004, 56(3), 387-437.
3. Marnett, L.J. The COXIB experience: A look in the rear-viewmirror. Ann. Rev. Pharmacol. Toxicol., 2009, 49, 26.
4. Antman, E.M.; Bennett J.S.; Daugherty A.; Furberg, C.; Roberts, H.; Taubert, K.A. Use of nonsteroidal antiinflammatory drugs. An update for clinicians. Circulation, 2007, 115, 1634-1642.
5. Day, R.O.; Graham, G.G.; Williams, K.M. Pharmacokinetics ofnon-steroidal anti-inflammatory drugs. Clin. Rheumatol., 1988, 2, 363-393.
6. Warner, T.D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J. A.; Vane, J. R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxigenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA, 1999, 96, 7563-7568.
7. Singh, G.; Fort, J.G.; Goldstein, J.L.; Levy, R.A.; Hanrahan, P.S.; Bello, A.E.; Andrade-Ortega, L.; Wallemark, C.; Agrawal, N.M.; Eisen, G.M.; Stenson, W.F.; Triadafilopoulos, G. For the SUCCESS-I Investigators Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am. J. Med., 2006, 119, 255-266.
8. Singh, G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, rheumatism, and aging medical information system. Am. J. Ther., 2000, 7, 115-121.
9. Bjordal, J.M.; Ljunggren, A.E.; Klovning, A.; Slordal, L. Nonster-oidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: Meta-analysis of randomised placebo controlled trials. B.M.J., 2004, 329, 1317.
10. Hawkey, C.J.; Cullen, D.J.E.; Pearson, G.; Holmes, S.; Doherty, S.; Wilson, J.V.; Garrud, P.; Garner, S.; Maynard, A.; Logan, R.F.A. Pharmacoepidemiology of non-steroidal antinflammatory drug use in Nottingham general practices. Aliment. Pharmacol. Ther., 2000, 14, 177-185.
11. Lanas, A.; Ferrandez, A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging, 2007, 24, 121-131.
12. Wilcox, C.M.; Cryer, B.; Triadafilopoulos G. Patterns of use andpublic perception of over-the-counter pain relievers: Focus on nonsteroidal antiinflammatory drugs. J. Rheumatol., 2005, 32, 2218-2224.
13. Chen, Y-F.; Jobanputra, P.; Barton, P.; Bryan, S.; Fry-Smith, A.; Harris, G.; Taylor, R.S. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: A systematic review and economic evaluation. Health Technol. Assess., 2008, 12, 1-278.
14. Vane, J.R. Inhibition of prostaglandin synthesis as a mechanism ofaction for aspirin-like drugs. Nat. New. Biol., 1971, 43, 232-235.
15. Vane, J.R. The mode of action of aspirin and similar compounds. J. Allergy Clin. Immunol., 1976, 58, 691-712.
16. Vane, J.R.; Bakhle, Y.S.; Botting, R.M. Cyclooxygenases 1 and 2.Ann. Rev. Pharmacol. Toxicol., 1998, 38, 97-120.
17. Smith, W.L.; DeWitt, D.L.; Garavito, R.M. Cyclooxygenases:structural, cellular, and molecular biology. Ann. Rev. Biochem., 2000, 69, 145-182.
18. Murphy, J.F.; Fitzgerald, D.J. Vascular endothelial growth factorinduces cyclooxygenase-dependent proliferation of endothelial cells via the VEGF-2 receptor. FASEB J., 2001, 15, 1667-1669.
19. Funk, C.D. Prostaglandins and leukotrienes: Advances in eicosa-noid biology. Science, 2001, 294, 1871-1875.
20. Patrignani, P.; Panara, M.R.; Greco, A.; Fusco, O.; Natoli, C.; Iacobelli, S.; Cipollone, F.; Ganci, A.; Creminon, C.; Maclouf, J. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther., 1994, 271, 1705-1712.
21. Hoffmann, C. COX-2 in brain and spinal cord implications fortherapeutic use. Curr. Med. Chem., 2000, 7, 1113-1120.
22. Harris, R.C.; McKanna, J.A.; Akai, Y.; Jacobson, H.R.; Dubois, R. N.; Breyer, M.D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest., 1994, 94, 2504-2510.
23. Jones, D.A.; Carlton, D.P.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem., 1993, 268, 9049-9054.
24. Asano, K.; Nakamura, H.; Lilly, C.M.; Klagsbrun, M.; Drazen, J.M. Interferon gamma induces prostaglandin G/H synthase-2through an autocrine loop via the epidermal growth factor receptor in human bronchial epithelial cells. J. Clin. Invest., 1997, 99, 1057-1063.
25. Shemesh, M.; Gurevich, M.; Mizrachi, D.; Dombrovski, L.; Stram, Y.; Fields, M.J.; Shore, L.S. Expression of functional luteinizing hormone (LH) receptor and its messenger ribonucleic acid in bovine uterine veins: LH induction of cyclooxygenase and augmentation of prostaglandin production in bovine uterine veins. Endocrinology, 1997, 138, 4844-4851.
26. Tamura, M.; Sebastian, S.; Gurates, B., Yang, S.; Fang, Z.; Bulun, S. E. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells. J. Clin. Endocrinol. Metab., 2002, 87, 3504-3507.
27. Di Popolo, A.; Memoli, A.; Apicella, A.; Tuccillo, C.; di Palma, A.; Ricchi, P.; Acquaviva, A.M.; Zarrilli, R. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene, 2000, 19, 5517-5524.
28. Jones, M.K.; Wang, H.; Peskar, B.M.; Levin, E.; Itani, R.M.; Sar-feh, I.J.; Tarnawski, A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med., 1999, 5, 1418-1423.
29. Pichiule, P.; Chavez, J.C.; LaManna, J.C. Hypoxic regulation ofangiopoietin-2 expression in endothelial cells. J. Biol. Chem., 2004, 279, 12171-12180.
30. Lukiw, W.J.; Ottlecz, A.; Lambrou, G.; Grueninger, M.; Finley, J.; Thompson, H.W.; Bazan, N.G. Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest. Ophthalmol. Vis. Sci., 2003, 44, 4163-4170.
31. Masferrer, J.L.; Leahy, K.M.; Koki, A.T.; Zweifel, B.S.; Settle, S. L.; Woerner, B.M.; Edwards, D.A.; Flickinger, A.G.; Moore, R.J.; Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 2000, 60, 1306-1311.
32. Chandrasekharan, N.V.; Dai, H.; Roos, K.L.; Evanson, N.K.; Tom-sik, J.; Elton, T.S.; Simmons, D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc. Natl. Acad. Sci. USA, 2002, 99, 13926-13931.
33. Snipes, J.A.; Kis, B.; Shelness, G.S.; Hewett, J.A.; Busija, D.W. Cloning and characterization of cyclooxygenase-1b (putative cyclooxygenase-3 in rat. J. Pharmacol. Exp. Ther., 2005, 313, 668-676.
34. Jones, R. Nonsteroidal anti-inflammatory drug prescribing: past,present, and future. Am. J. Med., 2001, 110, 4-7.
35. Hernandez-Diaz, S.; Rodriguez, L.A. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: An overview of epidemiologic studies published in the 1990s. Arch. Intern. Med., 2000, 160, 2093-9.
36. Silverstein, F.E.; Faich, G.; Goldstein, J.L.; Simon, L.S.; Pincus, T.; Whelton, A. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA, 2000, 284, 1247-1255.
37. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; BurgosVar-gas, R.; Davis, B. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 2000, 343, 1520-8.
38. Schnitzer, T.J.; Burmester, G.R.; Mysler, E.; Hochberg, M. C.; Doherty, M.; Ehrsam, E. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet, 2004, 364, 665-74.
39. Garcìa Rodrìguez, L.A.; Barreales Tolosa, L. Risk of upper gas-trointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology, 2007, 132, 498-506.
40. Iseki, S. Immunocytochemical localization of cyclooxygenase-1and cyclooxygenase-2 in the rat stomach. Histochem. J., 1995, 27, 323-328.
41. Zimmermann, K.C.; Sarbia, M.; Schror, K.; Weber, A.A. Constitu-tive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol. Pharmacol., 1998, 54, 536-40.
42. McCartney, S.A.; Mitchell, J.A.; Fairclough, P.D.; Farthing, M. J. G.; Warner, T.D. Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment. Pharmacol. Ther., 1999, 13, 1115-7.
43. Wallace, J.L.; McKnight, W.; Reuter, B.K.; Vergnolle, N. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology, 2000, 119, 706-14.
44. McAdam, B. F.; Catella-Lawson, F.; Mardini, I. A.; Kapoor, S.; Lawson, J. A.; FitzGerald, G. A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA, 1999, 96, 272-277.
45. Loftin, C. D.; Trivedi, D. B; Tiano, H. F.; Clark, J. A.; Morham, S.G.; Breyer, M. D.; Nguyen, M.; Hawkins, B. M.; Golet, J. L.; Smithies, O.; Koller, B. H.; Lagenbach, R. Failure of ductus arteiosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cycloxygenase-2. Proc. Natl. Acad. Sci. USA, 2001, 98, 1059-1064.
46. Mukherjee, D.; Nissen, S. E.; Topol, E.J. Risk of cardiovascularevents associated with selective COX-2 inhibitors. JAMA, 2001, 286, 954-959.
47. Adderley, S.R.; FitzGerald, D.J. Oxidative damage of cardiomyo-cytes is limited by extracellular regulated kinases 1/2 mediated induction of cyclooxygenanse-2. J. Biol. Chem., 1999, 274, 5038-5046.
48. Mitchell, J.A.; Warner, T.D. COX isoforms in the cardiovascularsystem: Understanding the activities of nonsteroidal antiinflammatory drugs. Nat. Rev. Drug. Dis., 2006, 5, 75-86.
49. García Rodríguez, L.A.; Tacconelli, S.; Patrignani, P. Role of dosepotency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol., 2008, 52, 1628-36.
50. Hernandez-Diaz, S.; Varas-Lorenzo, C.; Garcia Rodriguez, L.A. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin. Pharmacol. Toxicol., 2006, 98, 266-274.
51. Kearney, P.M.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J.R.; Patrono, C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ., 2006, 332, 1302-1308.
52. Hermann, M.; Camici, G.; Fratton, A.; Hurlimann, D.; Tanner, F. C.; Hellermann, J.P. Differential effects of selective cyclooxygenase2 inhibitors on endothelial function in salt-induced hypertension. Circulation, 2003, 108, 2308-11.
53. Sowers, J.R.; White, W.B.; Pitt, B.; Whelton, A.; Simon, L. S.; Winer, N. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch. Intern. Med., 2005, 165, 161-8.
54. Zhang, J.; Ding, E.L.; Song, Y. Adverse effects of cyclooxygenase2 inhibitors on renal and arrhythmia events: Meta-analysis of randomized trials. JAMA, 2006, 296, 1619-32.
55. Capone, M.L.; Tacconelli, S.; Garcia Rodriguez, L.; Patrignani, P. NSAIDs and cardiovascular disease: Trasducing human pharmacology results into clinical read-outs in the general population. Pharmacological Reports, 2010, 62, 530-535.
56. Cheng, Y.; Wang, M.; Yu, Y.; Lawson, J.; Funk, C.D.; Fitzgerald, G. A. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest., 2006, 116, 1391-1399.
57. Feldman, H.; Kinman, J.; Berlin, J.; Hennessy, S.; Kimmen, S. E.; Farrar, J. Parenteral ketorolac: The risk of acute renal failure. Ann. Intern. Med., 1997, 126, 193-9.
58. Fitzgerald, G.A.; Patrono, C. The coxibs, selective inhibitors ofcyclooxygenase-2. N. Eng. J. Med., 2001, 345, 433-442.
59. Ye, W.; Zhang, H.; Hillas, E.; Kohan, D.E.; Miller, R.L.; Nelson, R. D.; Honeggar, M.; Yang, T. Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. Am. J. Renal. Physiol., 2006, 290, 542-549.
60. Khanna, A.; White, W.B. The management of hyperkalemia inpatients with cardiovascular disease. Am. J. Med., 2009, 122, 215-221.
61. Hisham, A.; Wanzhu, Tu.; Richard, A.; Hansen, S.; Blalock, D.; Craig, B.; Michael D. Murray Risk of hyperkalemia associated with selective COX-2 inhibitors. Pharmacoepidemiol and Drug safety, 2010, 19, 1194-1198.
62. Agúndez, J.A.; Lucena, M.I.; Martínez, C.; Andrade, R.J.; Blanca, M.; Ayuso, P.; García-Martín, E. Assessment of nonsteroidal antiinflammatory drug-induced hepatotoxicity. Expert. Opin. Drug Metab. Toxicol., 2011, 7,(7), 817-28.
63. Teoh, N.C.; Farrell, G.C. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin. Liver Dis., 2003, 7, 401-413.
64. Aithal, G.P.; Day, C.P. Nonsteroidal anti-inflammatory drugin-duced hepatotoxicity. Clin Liver Dis., 2007, 11, 563-575.
65. Kuehn, B.M.; FDA focuses on drugs and liver damage: Labelingand other changes for acetaminophen. JAMA, 2009, 302, 369-71.
66. Abnet, C.C.; Freedman, N.D.; Kamangar, F.; Leitzmann, M. F.; Hollenbeck, A.R.; Schatzkin, A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: Results from a cohort study and a meta-analysis. Br. J. Cancer, 2009, 100, 551-557.
67. Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin and the risk of colorec-tal cancer in relation to the expression of COX-2. N. Engl. J. Med., 2007, 356, 2131-2142.
68. Takkouche, B.; Regueira-Méndez, C.; Etminan, M. Breast cancerand use of nonsteroidal anti-inflammatory drugs: A meta-analysis, J. Natl. Cancer Inst., 2008, 100, 1439-1447.
69. Jacobs, E.J.; Rodriguez, C.; Mondul, A.M.; Connell, C.J.; Henley, S. J.; Calle, E.E.; Thun, M.J. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl. Cancer Inst., 2005, 97, 975-980.
70. Slatore, C.G.; Au, D.H.; Littman, A.J.; Satia, J.A.; White, E. Asso-ciation of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study, Cancer Epidemiol. Biomarkers Prev., 2009, 18, 1203-1207.
71. Cuzick, J.; Otto, F.; Baron, J.A.; Brown, P.H.; Burn, J.; Greenwald, P.; Jankowski, J.; La Vecchia, C.; Meyskens, F.; Senn, H.J.; Thun, M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement, Lancet Oncol., 2009, 10, 501-507.
72. Kanaoka, S.; Takai, T.; Yoshida, K. Cyclooxygenase-2 and tumorbiology. Adv. Clin. Chem., 2007, 43, 59-78.
73. Zhu, J.X.; Song, X.Q.; Lin, H. P.; Young, D.C.; Yan, S.Q.; Mar-quez, V.E.; Chen, C. S. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosisinducing agents. J. Natl. Cancer Inst., 2002, 95, 1745-1757.
74. Grösch, S.; Maier, T. J.; Schiffmann, S.; Geisslinger, G. Cyclooxy-genase-2 (COX-2) independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst., 2006, 98, 736-747.
75. Brown, J.R.; DuBois, R.N. COX-2: a molecular target for colorec-tal cancer prevention, J. Clin. Oncol., 2005, 23, 2840-2855.
76. Wang, D.; Dubois, R.N. Prostaglandins and cancer, Gut, 2006, 55,115-122.
77. Samuelsson, B.; Morgenstern, R.; Jakobsson, P.J. Membrane pros-taglandin E synthase-1: A novel therapeutic target. Pharmacol. Rev., 2007, 59,(3), 207-224.
78. Sakai, H.; Suzuki, T.; Takahashi, Y.; Ukai, M.; Tauchi, K.; Fujii, T.; Horikawa, N.; Minamimura, T.; Tabuchi, Y.; Morii, M.; Tsukada, K.; Takeguchi, N. Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2. FEBS, 2006, 580, 3368-3374.
79. Zamuner, S.R.; Bak, A.W.; Devchand, P.R.; Wallace, J.L. Predis-position to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. Am. J. Pathol., 2005, 167, 1293-1300.
80. Giardiello, F.M.; Spannhake, E.W.; DuBois, R.N.; Hylind, L. M.; Robinson, C.R.; Hubbard, W.C.; Hamilton, S.R.; Yang, V.W. Prostaglandin levels in human colorectal mucosa: Effects of sulindac in patients with familial adenomatous polyposis. Dig. Dis. Sci., 1998, 43, 311-316.
81. Grösch, S.; Tegeder, I.; Niederberger, E.; Bräutigam, L.; Geisslin-ger, G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxi. FASEB J., 2001, 15, 2742-2744.
82. Farrow, D.C.; Vaughan, T.L.; Hansten, P.D.; Stanford, J.L.; Risch, H. A.; Gammon, M.D.; Chow, W.H.; Dubrow, R.; Ahsan, H.; Mayne, S.T.; Schoenberg, J. B.;. West, A.B; Rotterdam, H.; Fraumen Jr., J.F.; Blot, W.J. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers, 1998, 7, 97-102.
83. Harris, R.E.; Beebe-Donk, J.; Doss, H.; Burr Doss, D. Aspirin,ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol. Rep., 2005, 13, 559-583.
84. Rothwell, P.M.; Fowkes, F.G.; Belch, J.F.; Ogawa, H.; Warlow, C. P.; Meade, T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 2011, 377, 31-41.
85. Husain, S.S.; Szabo, I.L.; Tamawski, A.S. NSAID inhibition of GIcancer growth: Clinical implications and molecular mechanisms of action. Am. J. Gastroenterol., 2002, 97, 542-553.
86. Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin and the risk of colorec-tal cancer in relation to the expression of COX-2. N. Engl. J. Med., 2007, 356, 2131-2142.
87. Rothwell, P.M.; Wilson, M.; Elwin, C.E.; Norrving, B.; Algra, A.; Warlow, C.P.; Meade, T.W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet, 2010, 376, 1741-1750.
88. Sanyal, S.N.; Kaur, J. Induction of apoptosis as a potential chemo-preventive effect of dual cycloxygenase inhibitor, diclofenac, in early colon carcinogenesis. J. Environ. Pathol. Toxicol. Oncol., 2010, 29, 41-53.
89. Fecker, L.F.; Stockfleth, E.; Braun, F.K.; Rodust, P.M.; Schwarz, C. Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP. J. Invest. Dermatol., 2010, 130, 2098-2109.
90. Steinbach, G.; Lynch, P.M.; Phillips, R.K.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; Su, L.K.; Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 2000, 342, 1946-1952.
91. Arber, N.; Eagle, C.J.; Spicak, J.; Rácz, I.; Dite, P.; Hajer, J.; Za-voral, M.; Lechuga, M.J.; Gerletti, P.; Tang, J.; Rosenstein, R.B.; Macdonald, K.; Bhadra, P.; Fowler, R.; Wittes, J.; Zauber, A.G.; Solomon, S.D.; Levin, B. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med., 2006, 355, 885-895.
92. Grösch, S.; Thorsten, J.M.; Schiffmann, S.; Geisslinger, G. Cy-clooxygenase-2 (COX-2) Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. J. Natl. Cancer Inst., 2006, 98, 11.
93. Bresalier, R.S.; Sandler, R.S.; Quan, H.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 2005, 352, 1092-1102.
94. Wakimoto, N.; Wolf, I.; Yin, D.; O'Kelly, J.; Akagi, T.; Abramovitz, L.; Black, K.L.; Tai, H.H.; Koeffler, H.P. Nonsteroidal anti-inflammatory drugs suppress glioma via 15hydroxyprostaglandin dehydrogenase. Cancer Res., 2008, 68, 6978-6986.
95. Wernli, K.J.; Newcomb, P.A.; Hampton, J.M.; Trentham-Dietz, A.; Egan K.M. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br. J. Cancer, 2008, 98, 1781-1783.
96. Rodriguez-Burford, C.; Barnes, M.N.; Oelschlager, D.K.; Myers, R.B.; Talley, L.I. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin. Cancer Res., 2002, 8, 202-209.
97. Zerbini, L.F.; Tamura, R.E.; Correa, R.G.; Czibere, A.; Cordeiro, J.; Bhasin, M.; Simabuco, F.M.; Wang, Y.; Gu, X.; Li, L.; Sarkar, D.; Zhou, Jin-R.; Fisher, P. B.; Libermann, T.A. Combinatorial effect of non steroidal anti-inflammatory drugs and NF-kB inhibitors in ovarian cancer therapy. 2011, PloS ONE 6(9), e 24285.
98. Cacquevel, M.; Lebeurrier, N.; Cheenne, S.; Vivien, D. Cytokinesin neuroinflammation and Alzheimer's disease. Curr. Drug Targets, 2004, 5, 529-534.
99. Shaftel, S.S.; Griffin, W.S.T.; O'Banion, M.K. The role of interleu-kin-1 in neuroinflammation and Alzheimer disease: An evolving perspective. J. Neuroinflamm., 2008, 5, 12.
100. Cimino, P.J.; Keene, C.D.; Breyer, R.M.; Montine, K.S.; Montine, T. J. Therapeutic targets in prostaglandin E-2 signaling for neurologic disease. Curr. Med. Chem., 2008, 15, 1863-1869.
101. Brown, G.C.; Bal-Price, A. Inflammatory neurodegeneration medi-ated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol., 2003, 27, 325-355.
102. Calabrese, V.; Bates, T.E.; Stella, A.M.G. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: The role of oxidant/antioxidant balance. Neurochem. Res., 2000, 25, 1315-1341.
103. Munhoz, C.D.; García-Bueno, B.; Madrigal, J.L.M.; Lepsch, L.B.; Scavone, C.; Leza, J.C. Stress-induced neuroinflammation: mechanisms and new pharmacological targets. Braz. J. Medl. Biol. Res., 2008, 41, 1037-1046.
104. Meda, L.; Baron, P.; Scarlato, G. Glial activation in Alzheimer'sdisease: The role of Abeta and its associated proteins. Neurobiol. Aging, 2001, 22, 885-893.
105. Fujimi, K.; Noda, K.; Sasaki, K.; Wakisaka, Y.; Tanizaki, Y.; Iida, M.; Kiyohara, Y.; Kanba, S.; Iwaki, T. Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease: The Hisayama study. Dement. Geriatr. Cogn. Disord., 2007, 23, 423-431.
106. Hoozemans, J.J.M.; Rozemuller, J.M.; van Haastert, E.S.; Veer-huis, R.; Eikelenboom, P. Cyclooxygenase-1 and-2 in the different stages of Alzheimer's disease pathology. Curr. Pharm. Design, 2008, 14, 1419-1427.
107. Yermakova, A.V.; O'Banion, M.K. Downregulation of neuronalcyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol. Aging, 2001, 22, 823-836.
108. McGeer, P.L. Cyclo-oxygenase-2 inhibitors: Rationale and thera-peutic potential for Alzheimer's disease. Drugs Aging, 2000, 17, 1-11.
109. Rogers, J.; Kirby, L.C.; Hempelman, S.R.; Berry, D.L.; McGeer, P.L.; Kaszniak, A.W.; Zalinski, J.; Cofield, M.; Mansukhani, L.; Willson, P. Clinical trial of indomethacin in Alzheimer's disease. Neurology, 1993, 43, 1609-1611.
110. Aisen, P.S.; Schafer, K.A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K.L.; Farlow, M.R.; Jin, S.; Thomas, R.G.; Thal, L.J. Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: A randomized controlled trial. JAMA, 2003, 289, 2819-2826.
111. De Jong, D.; Jansen, R.; Hoefnagels, W.; Jellesma-Eggenkamp, M.; Verbeek, M.; Borm, G.; Kremer, B. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: A randomized controlled trial. PloS ONE, 2008, 3, e1475.
112. Pasqualetti, P.; Bonomini, C.; Dal Forno, G.; Paulon, L.; Sinforiani, E.; Marra, C.; Zanetti, O.; Rossini, P.M. A randomized controlledstudy on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin. Exp. Res., 2009, 21, 102-110.
113. Reines, S.A.; Block, G.A.; Morris, J.C.; Liu, G.; Nessly, M.L.; Lines, C.R.; Norman, B.A.; Baranak, C.C. Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology, 2004, 62, 66-71.
114. Soininen, H.; West, C.; Robbins, J.; Niculescu, L. Long-term effi-cacy and safety of celecoxib in Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2007, 23, 8-21.
115. Aisen, P.S.; Schmeidler, J.; Pasinetti, G.M. Randomized pilot studyof nimesulide treatment in Alzheimer's disease. Neurology, 2002, 58, 1050-1054.
116. McGeer, P.L.; McGeer, E.G. NSAIDs and Alzheimer disease:Epidemiological, animal model and clinical studies. Neurobiol. Aging, 2007, 28, 639-647.
117. Townsend, K.P.; Pratico, D. Novel therapeutic opportunities forAlzheimer's disease: Focus on nonsteroidal anti-inflammatory drugs. FASEB J., 2005, 19, 1592-1601.
118. Martin, B.K.; Szekely, C.; Brandt, J.; Piantadosi, S.; Breitner, J.C.S.; Craft, S.; Evans, D.; Green, R.; Mullan, M.; Grp, A.R. Cognitive function over time in the Alzheimer's disease antiinflammatory prevention trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neur., 2008, 65, 896-905.
119. Couzin, J. Clinical trials: Halt of Celebrex study threatens drug'sfuture, other trials. Science, 2004, 306, 2170-2170.
120. Wyss-Coray, T; Joseph Rogers J. Inflammation in Alzheimer Dis-ease-A Brief Review of the Basic Science and Clinical Literature. Cold Spring Harb. Perspect. Med., 2012, 2, a006346.
121. Small, G.W.; Siddarth, P.; Silverman, D.H.; Ercoli, L.M.; Miller, K.J.; Lavretsky, H.; Bookheimer, S.Y.; Huang, S.C.; Barrio, J.R.; Phelps, M.E. Cognitive and cerebral metabolic effects of celecoxib vs. placebo in people with age-related memory loss: Randomized controlled study. Am. J. Geriatr. Psychiatry, 2008, 16, 999-1009.
122. Cowley, T.R.; Fahey, B.; O'Mara, S.M. COX-2, but not COX-1,activity is necessary for the induction of perforant path long-termpotentiation and spatial learning in vivo. Eur. J. Neurosci., 2008, 27, 2999-3008.
123. Guzman, C.B.; Graham, K.A.; Grace, L.A.; Moore, A.H. Sexdependent effect of cyclooxygenase-2 inhibition on mouse spatialmemory. Behav. Brain Rev., 2009, 199, 355-359.
124. Rall, J.M.; Mach, S.A.; Dash, P.K. Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats. Brain Res., 2003, 968, 273-276.
125. Sharifzadeh, M.; Naghdi, N.; Khosrovani, S.; Ostad, S.N.; Sharifzadeh, K.; Roghani, A. Post-training intrahippocampal infu-sion of the COX-2 inhibitor celecoxib impaired spatial memory retention in rats. Eur. J. Pharmacol., 2005, 511, 159-166.
126. Teather, L.A.; Packard, M.G.; Bazan, N.G. Post-training cyclooxygenase-2 (COX-2) inhibition impairs memory consolidation. Learn.Memory, 2002, 9, 41-47.
127. Choi, S.H.; Aid, S.; Bosetti, F. The distinct roles of cyclooxygenase-1 and-2 in neuroinflammation: Implications for transla-tional research. Trends Pharmacol. Sci., 2009, 30, 174-181.
128. Vlad, S.C.; Miller, D.R.; Kowall, N.W.; Felson, D.T. Protectiveeffects of NSAIDs on the development of Alzheimer disease. Neurology, 2008, 70, 1672-1677.
129. Waldstein, S.R.; Wendell, C.R.; Seliger, S.L.; Ferrucci, L.; Metter, E.J.; Zonderman, A.B. Nonsteroidal anti-inflammatory drugs, Aspirin, and cognitive function in the Baltimore longitudinal study of aging. J. Amer. Geriat. Soc., 2010, 58, 38-43.
130. Hein, A.M.; Stasko, M.R.; Matousek, S.B.; Scott-McKean, J.J.; Maier, S.F.; Olschowka, J.A.; Costa, A.C.S.; O'Banion, M.K. Sustained hippocampal IL-1 overexpression impairs contextual and spatial memory in transgenic mice. Brain Behav. Immun., 2009, 24, 243-253.
131. McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E.G. Reactivemicroglia are positive for HLA-DR in the substantia nigra of parkinsons and alzheimers-disease brains. Neurology, 1988, 38, 1285-1291.
132. Tansey, M.G.; Goldberg, M.S. Neuroinflammation in Parkinson'sdisease: Its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis., 2010, 37, 510-518.
133. Wilms, H.; Zecca, L.; Rosenstiel, P.; Sievers, J.; Deuschl, G.; Lu-cius, R. Inflammation in Parkinson's diseases and other neurodegenerative diseases: Cause and therapeutic implications. Curr. Pharm. Design, 2007, 13, 1925-1928.
134. Wang, T.G.; Pei, Z.; Zhang, W.; Liu, B.; Langenbach, R.; Lee, C.; Wilson, B.; Reece, J.M.; Miller, D.S.; Hong, J.S. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J., 2005, 19, 1134-1136.
135. Teismann, P.; Tieu, K.; Choi, D.K.; Wu, D.C.; Naini, A.; Hunot, S.; Vila, M.; Jackson-Lewis, V.; Przedborski, S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Nat. Acad. Sci. USA, 2003, 100, 5473-5478.
136. Feng, Z.H.; Wang, T.G.; Li, D.D.; Fung, P.; Wilson, B.C.; Liu, B.; Ali, S.F.; Langenbach, R.; Hong, J.S. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1,2,3,6-tetrahydropyridineinduced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett., 2002, 329, 354-358.
137. Przedborski, S.; Goldman, J.E. Pathogenic role of glial cells inParkinson's disease. Advan. Mol. Cell. Biol., 2004, 31, 967-982.
138. Hirsch, E.C.; Hunot, S. Neuroinflammation in Parkinson's disease:A target for neuroprotection. Lancet Neurol., 2009, 8, 382-397.
139. Esposito, E.; Di Matteo, V.; Benigno, A.; Pierucci, M.; Cresci-manno, G.; Di Giovanni, G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol., 2007, 205, 295-312.
140. Chen, H.; Zhang, S.M.; Hernan, M.A. Nonsteroidal antiinflamma-tory drugs and the risk of Parkinson disease. Arch. Neurol., 2006, 60, 1059-1064.
141. Chen, H.; Jacobs, E.; Schwarzschild, M.A. Nonsteroidal antiin-flammatory drug use and the risk for Parkinson's disease. Ann. Neurol., 2005, 58, 963-967.
142. Samii, A.; Etminan, M.; Wiens, M.O.; Jafari, S. NSAID use and therisk of Parkinson's disease systematic review and meta-analysis of observational studies. Drug Aging, 2009, 26, 769-779.
143. Gao, X.; Chen, H.; Schwarzschild, M.A.; Ascherio, A. Use ofibuprofen and risk of Parkinson disease. Neurology, 2011, 76, 863-869.
144. Whittle, B.J. Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer antiinflammatory drugs. Curr. Opin. Pharmacol., 2004, 4, 538-45.
145. Moncada, S.; Palmer, R.M.J.; Higgs, E.A. Nitric oxide: physiology,pathophysiology, and pharmacology. Pharmacol. Rev., 1991, 43, 109-42.
146. Wallace, J.L.; Miller, M.J.S. Nitric oxide in mucosal defense: alittle goes a long way. Gastroenterology, 2000, 119, 512-20.
147. Wallace, J.L.; Del Soldato, P. The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol., 2003, 17, 11-20.
148. Cirino, G. Nitric oxide releasing drugs: from bench to bedside. Dig.Liver Dis., 2003, 35, S2-8.
149. Keeble, JE.; Moore, P.K. Pharmacology and potential therapeuticapplications of nitric oxide-releasing non-steroidal antiinflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol., 2002, 137, 295-310.
150. Fiorucci, S, Distrutti, E. Cyclo-oxygenase (COX) inhibiting nitricoxide donating (CINODs) drugs: a review of their current status. Curr. Top. Med. Chem., 2007, 7, 277-82.
151. Davies, N.M.; Roseth, A.G.; Appleyard, C.B. NO-naproxen vs.naproxen: ulcerogenic, analgesic and antiinflammatory effects. Alimen. Pharmacol. Ther., 1997, 11, 69-79.
152. Elliott, S.N.; McKnight, W.; Cirino, G.; Wallace, J.L. A nitricoxide-releasing nonsteroidal antiinflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology, 1995, 109, 524-30.
153. Ukawa, H.; Yamakuni, H.; Kato, S.; Takeuchi, K. Effects of cy-clooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach. Dig. Dis. Sci., 1998, 43, 2003-11.
154. Burgaud, J.L.; Ongini, E.; Del Soldato, P. Nitric oxide-releasingdrugs: a novel class of effective and safe therapeutic agents. Ann.N. Y. Acad. Sci., 2002, 962, 360-71.
155. Fiorucci, S.; Santucci, L.; Gresele, P.; Faccino, R.M.; Del Soldato, P.; Morelli, A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology, 2003, 124, 600-7.
156. Hawkey, C.J.; Jones, J.I.; Atherton, C.T. Gastrointestinal safety ofAZD3582, a cyclooxygenase inhibiting nitric oxide donator: Proof of concept study in humans. Gut., 2003, 52, 1537-42.
157. Jonzon, B.; Bjarnason, I.; Hawkey, C. The CINOD, AZD3582,exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers. Inflammopharmacology, 2003, 11, 437-44.
158. Hill, M.; Sindet-Pederson, S.; Seymour, R.A. Analgesic effects of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 inpostoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double blind, placebo-controlled studies. Clin. Ther., 2006, 28, 1279-95.
159. Chegaev, K.; Lazzarato, L.; Tosco, P. NO-Donor COX2 Inhibitors. New Nitrooxy-Substituted 1,5-Diarylimidazoles Endowedwith COX-2 Inhibitory and Vasodilator Properties. J. Med. Chem., 2007, 50, 1449-57.
160. Fiorucci, S.; Distrutti, E. COXIBs, CINODs and H2S-releasing NSAIDs: current perspectives in the development of safer non ster-oidal anti-inflammatory drugs. Curr. Med. Chem., 2011, 18, (23), 3494-505.
161. Namdev, B.; Asif Rahimkhan, P.; Somnath, H. Apparao Satyam Part 3: Nitric Oxide-Releasing Prodrugs of Non-steroidal Anti-inflammatory Drugs. Chem. Pharm. Bull., 2012, 60, (4), 465-481.
162. Fiorucci, S.; Distrutti, E.; Cirino, G.; Fallace, J.L. The emergingroles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology, 2006, 131, 259-71.
163. Wallace, J.L.; Caliendo, G.; Santagada, V.; Cirino, G.; Fiorucci, S.Gastrointestinal safety and antiinflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology, 2007, 132, 261-71.
164. Chattopadhyay, M.; Kodela, R.; Olson, K.R.; Kashfi, K. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem. Biophys. Res. Commun., 2012, 419, 3, 523-528.
165. Charlier, C.; Michaux, C. Dual inhibition of cyclooxygenase-2(COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer nonsteroidal anti-inflammatory drugs. Eur. J. Med. Chem., 2003, 38, 645-659.
166. Kulkarmi, S. K.; Singh, V.P. Licofelone a novel analgesic and anti-inflammatory agent Curr. Top. Med. Chem., 2007, 7, (3), 251-63.
167. Raynauld, J.P.; Martel-Pelletier, J.; Bias, P.; Laufer, S.; Haraoui, B.; Choquette, D.; Beaulieu, A.D.; Abram, F.; Dorais, M.; Vignon, E.; Pelletier, J.P. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: A first multicentre clinical trial using quantitative MRI. Ann. Rheum. Dis., 2009, 68, (6), 938-47.
168. Thoren, S.; Weinander, R.; Saha, S.; Jegerschold, C.; Pettersson, P.L.; Samuelsson, B.; Hebert, H.; Hamberg, M.; Morgenstern, R. J.; Akobsson, P. J. Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J. Biol. Chem., 2003, 278, 22199-22209.
169. Koeberle, A.; Pollastro, F.; Northoff, H.; Werz, O. Myrtucommu-lone, a natural acylphloroglucinol, inhibits microsomal prostaglandin E(2) synthase-1. Br. J. Pharmacol., 2009, 156, (6), 952-961.
170. Dallaporta M.; Pecchi E.; Thirion S.; Jean A.; Troadec J. Towardsthe manegement of inflammation: recent developments of mPGE1inhibitors. Recent Patents on CNS Drug Discovery, 2010, 5, 70-80.
171. Xu D.; Rowland S.E.; Clark P.; Giroux A.; Côté B.; Guiral S. MF63 [2-(6-chloro-1Hphenanthro [9,10-d]imidazol-2-yl) isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J. Pharmacol. Exp. Ther., 2008, 326, 754-63.
172. Wang M.; Zukas A.M.; Hui Y.; Ricciotti E.; Puré E.; Fitz Gerald G. A. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl. Acad. Sci. USA, 2006, 103, 14507-12.
173. Wang M.; Lee E.; Song W.; Ricciotti E.; Rader D.J.; Lawson J.A.; Pure E.; FitzGerald G.A. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation, 2008, 117, 1302-1309.
174. Anderson D.A.; Gentry C.; Alemnir L.; D. Killander Lewis S. E.; Anderson A.; Bucher B.; Galzi J-L.; Sterner O.; Bevan S.; Hogestatt E.D.; Zygmunt P.M. TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoidtetrahidrocannabiol. Nature Cominication, 2011, 2, 551, 22.
175. Baraldi P.G.; Preti D.; Materazzi S.; Geppetti P. Transient receptorpotential ankyrin 1 (TRPA1) chanel as emerging target for novel analgesic and anti-inflammatory agents. J. Med. Chem., 2010, 53, 5805-51.